What inhaler (puffer) is recommended for symptom relief in interstitial lung disease and what is the appropriate dosing regimen?

Inhaled Corticosteroids Are NOT Recommended for ILD Symptom Management

For patients with interstitial lung disease presenting with chronic cough, inhaled corticosteroids should NOT be routinely prescribed, as they lack evidence for symptom relief in this population 1. The CHEST guideline specifically recommends against inhaled corticosteroids for pulmonary sarcoidosis-related chronic cough (Grade 2C recommendation).

Key Clinical Approach

First: Rule Out Treatable Causes

Before considering any inhaler therapy, assess for:

• ILD progression requiring disease-modifying treatment
• Complications from immunosuppressive therapy (infections, drug side effects)
• Standard causes of acute/subacute/chronic cough per general cough guidelines 1

Why Traditional "Puffers" Don't Work in ILD

The mechanism of cough in ILD differs fundamentally from asthma or COPD:

• Cough results from mechanical distortion of fibrotic lung parenchyma
• Heightened cough reflex sensitivity
• Not primarily bronchospasm or airway inflammation 1

This explains why bronchodilators and inhaled corticosteroids—the typical "puffers"—are ineffective.

What Actually Works for ILD-Related Symptoms

For Refractory Chronic Cough:

The evidence-based approach follows this sequence:

1. Gabapentin (neuromodulator) - suggested as first-line for refractory cough 1
2. Multimodality speech pathology therapy 1
3. Opiates - reserved for severe cases adversely affecting quality of life, with reassessment at 1 week then monthly 1

For Pulmonary Hypertension Associated with ILD:

Inhaled treprostinil is the only FDA-approved inhaled therapy for ILD patients, specifically for those with pulmonary hypertension:

• Dosing regimen: Start at 3 breaths (18 μg) four times daily, titrate up to maximum 12 breaths (72 μg) four times daily 2, 3
• Administration: Via ultrasonic, pulsed-delivery nebulizer 2
• Evidence: Improved 6-minute walk distance by 31 meters, reduced NT-proBNP by 15%, and decreased clinical worsening (hazard ratio 0.61) at 16 weeks 2
• Indication: Only for documented pulmonary hypertension by right heart catheterization 2

Common Pitfalls to Avoid:

1. Don't prescribe PPIs for cough without documented GERD - specifically contraindicated in IPF patients with negative GERD workup 1

2. Don't use inhaled corticosteroids routinely - no evidence of benefit and specifically recommended against 1

3. Don't confuse inhaled treprostinil with traditional "puffers" - it's a prostacyclin analog for pulmonary hypertension, not a bronchodilator or steroid 2, 4

Disease-Modifying Treatments (Not "Puffers")

While not inhalers, the actual treatments that modify ILD progression include:

• Antifibrotics (nintedanib, pirfenidone) - oral medications that slow FVC decline by 44-57% 5
• Immunomodulators for CTD-ILD (mycophenolate, rituximab, tocilizumab) 6, 7

Bottom line: Traditional inhaler therapy (bronchodilators/inhaled steroids) has no role in ILD symptom management. For cough, use gabapentin or speech therapy. For PH-ILD with documented pulmonary hypertension, inhaled treprostinil is the evidence-based inhaled option.